Stock PROGEN PROSTATYPE GENOMICS AB
Add to a list
To use this feature you must be a member
Log inSign up

News Prostatype Genomics AB

Equities

PROGEN

SE0014684569

Market Closed - Nasdaq Stockholm
Other stock markets
 06:49:11 2024-04-30 am EDT 		5-day change 1st Jan Change
0.0416 SEK +7.22% Intraday chart for Prostatype Genomics AB +1.96% -56.21%
Apr. 18 Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala CI
Apr. 17 Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype® CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Prostatype Genomics publishes Annual Report for 2023
AQ
NOTICE OF ANNUAL GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)
AQ
Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3)
AQ
Prostatype Genomics announces very strong interim results from long-term follow-up study with Prostatype® in Uppsala
AQ
Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala
CI
Prostatype Genomics updates on significant progress in the US study with Prostatype®
AQ
Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®
CI
Prostatype Genomics Wraps Up Prostate Cancer Genetic Test Study with Positive Results
MT
Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain
AQ
Prostatype Genomics Announces Strong Positive Final Results from Multicentre Study with Prostatype®? in Spain
CI
Prostatype Genomics AB Announces Strong Positive Final Results from Multicentre Study with Prostatype in Spain
CI
The exercise period for Prostatype Genomic's warrants of series 3 begins today
AQ
Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States
AQ
Prostatype Genomics Enters into Collaboration with Professor E. David Crawford University of California San Diego, in Preparation for the Commercial Launch of Prostatype in the United States
CI
Prostatype Genomics publishes newsletter on US progress and the long-term follow-up study in Uppsala
AQ
Prostatype Genomics' long-term study with Uppsala University Hospital will be presented at the AUA conference in the US in May 2024
AQ
Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Prostatype Genomics publishes year-end report for 2023
AQ
Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market
AQ
Prostatype Genomics acquires CLIA Certificate to facilitate rapid US market launch with a significantly stronger financial outlook
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PROGEN Stock
  4. News Prostatype Genomics AB